Related Experiment Video

Updated: Jun 3, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

[siRNA-mediated inhibition of ErbB2 expression and its effect on breast cancer cell growth]

Kai Jiang1, Zhi-hong Yang, Zhao-yun Wang

  • 1Beijing Institute of Biotechnology, Beijing 100850, China. jiangkai@ymail.com

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi = Chinese Journal of Cellular and Molecular Immunology
|March 23, 2011
PubMed
Abstract

Insights

This study constructed ErbB2 small interfering RNA (siRNA) vectors that effectively inhibited ErbB2 expression. These ErbB2 siRNAs repressed the growth of ZR75-1 breast cancer cells, indicating therapeutic potential.

Area of Science:

  • Molecular biology
  • Cancer research
  • Gene silencing

Context:

  • ErbB2 overexpression is a hallmark of certain aggressive breast cancers.
  • Targeting ErbB2 is a key strategy in breast cancer therapy.
  • Small interfering RNA (siRNA) offers a precise method for gene knockdown.

Purpose:

  • To develop and validate ErbB2-specific siRNA constructs.
  • To assess the efficacy of these siRNAs in reducing ErbB2 expression.
  • To evaluate the impact of ErbB2 knockdown on the proliferation of ZR75-1 breast cancer cells.

Summary:

  • Two distinct ErbB2 siRNA sequences were designed and cloned into a mammalian expression vector.
  • Successful inhibition of both exogenous and endogenous ErbB2 protein levels was confirmed via Western blot analysis.
  • Transfection of these siRNA vectors significantly repressed the proliferation of ZR75-1 breast cancer cells.

Impact:

  • Demonstrates the potential of siRNA-mediated ErbB2 silencing as a therapeutic approach for ErbB2-positive breast cancers.
  • Provides a validated tool for further research into ErbB2-targeted cancer therapies.
  • Highlights the direct correlation between ErbB2 expression levels and cancer cell growth in relevant models.

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...